Skip to content

US · 21 CFR

21 CFR 601.32

General factors relevant to safety and effectiveness.

21 CFR Part 601 › Subpart D—Diagnostic Radiopharmaceuticals

Section text

FDA's determination of the safety and effectiveness of a diagnostic radiopharmaceutical includes consideration of the following:

(a) The proposed use of the diagnostic radiopharmaceutical in the practice of medicine;

(b) The pharmacological and toxicological activity of the diagnostic radiopharmaceutical (including any carrier or ligand component of the diagnostic radiopharmaceutical); and

(c) The estimated absorbed radiation dose of the diagnostic radiopharmaceutical.

Source: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · retrieved 2026-11-16

Weekly Newsletter

Get the week's FDA, EU and MFDS inspection findings

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Confirm by email to start · Unsubscribe any time